BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Roche (RHHBY) Wins UK National Institute for Clinical Excellence (NICE) Backing for Tarceva in Advanced Lung Cancer


5/10/2012 6:32:54 AM

Roche Holding AG (ROG)’s Tarceva lung- cancer medicine won the backing of the U.K.’s health-cost agency after presenting data comparing the drug with AstraZeneca Plc (AZN)’s Iressa, which is already recommended. Tarceva is a cost-effective option for patients with locally advanced or metastatic non-small cell lung cancer whose disease has a certain gene mutation, the London-based National Institute for Health and Clinical Excellence, known as NICE, said today in a statement. The Basel, Switzerland-based company agreed to give the state-run National Health Service a discount, and the amount is confidential.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->